These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10588330)

  • 1. Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies.
    Zoulim F
    Antiviral Res; 1999 Nov; 44(1):1-30. PubMed ID: 10588330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular virology of hepatitis B virus and targets for antiviral intervention.
    Glebe D; König A
    Intervirology; 2014; 57(3-4):134-40. PubMed ID: 25034480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Chronic hepatitis B. Recent advances in diagnosis and treatment].
    Bernardi M; Biselli M; Gramenzi A
    Recenti Prog Med; 2002; 93(7-8):397-402. PubMed ID: 12138683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Latest developments in the treatment of hepatitis B.
    Dandri M; Petersen J
    Minerva Gastroenterol Dietol; 2016 Mar; 62(1):88-102. PubMed ID: 26448309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiviral agents for the therapy of chronic hepatitis B virus infection.
    Zoulim F; Trepo C
    Intervirology; 1999; 42(2-3):125-44. PubMed ID: 10516467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance.
    Papatheodoridis GV; Dimou E; Papadimitropoulos V
    Am J Gastroenterol; 2002 Jul; 97(7):1618-28. PubMed ID: 12135009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F
    Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy of chronic hepatitis B: can we clear the virus and prevent drug resistance?
    Zoulim F
    Antivir Chem Chemother; 2004 Nov; 15(6):299-305. PubMed ID: 15646643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variable influence of mutational patterns in reverse-transcriptase domain on replication capacity of hepatitis B virus isolates from antiviral-experienced patients.
    Ji D; Liu Y; Si LL; Li L; Chen GF; Xin SJ; Zhao JM; Xu D
    Clin Chim Acta; 2011 Jan; 412(3-4):305-13. PubMed ID: 21056552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy.
    Ohsaki E; Suwanmanee Y; Ueda K
    Viruses; 2021 Aug; 13(9):. PubMed ID: 34578273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.
    Enomoto M; Tamori A; Kohmoto MT; Morikawa H; Habu D; Sakaguchi H; Takeda T; Seki S; Kawada N; Shiomi S; Nishiguchi S
    J Med Virol; 2007 Nov; 79(11):1664-70. PubMed ID: 17854034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.
    Allweiss L; Volz T; Giersch K; Kah J; Raffa G; Petersen J; Lohse AW; Beninati C; Pollicino T; Urban S; Lütgehetmann M; Dandri M
    Gut; 2018 Mar; 67(3):542-552. PubMed ID: 28428345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis B Virus Capsid Assembly Modulators, but Not Nucleoside Analogs, Inhibit the Production of Extracellular Pregenomic RNA and Spliced RNA Variants.
    Lam AM; Ren S; Espiritu C; Kelly M; Lau V; Zheng L; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus receptors and molecular drug targets.
    Verrier ER; Colpitts CC; Sureau C; Baumert TF
    Hepatol Int; 2016 Jul; 10(4):567-73. PubMed ID: 26979861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV replication inhibitors.
    Pierra Rouviere C; Dousson CB; Tavis JE
    Antiviral Res; 2020 Jul; 179():104815. PubMed ID: 32380149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of hepatitis B virus resistance development.
    Warner N; Locarnini S
    Intervirology; 2014; 57(3-4):218-24. PubMed ID: 25034491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.